Vercirnon sodium
Modify Date: 2024-01-12 11:36:52
Vercirnon sodium structure
|
Common Name | Vercirnon sodium | ||
|---|---|---|---|---|
| CAS Number | 886214-18-2 | Molecular Weight | 466.91300 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H20ClN2NaO4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Vercirnon sodiumVercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 µM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively[1]. |
| Name | sodium,(Z)-[(6E)-6-(4-tert-butylphenyl)sulfonylimino-3-chlorocyclohexa-2,4-dien-1-ylidene]-(1-oxidopyridin-1-ium-4-yl)methanolate |
|---|---|
| Synonym | More Synonyms |
| Description | Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 µM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively[1]. |
|---|---|
| Related Catalog | |
| Target |
CCR9:10 nM (IC50) |
| In Vitro | Vercirnon (GSK-1605786) sodium inhibits chemotaxis of primary CCR9-expressing cells to CCL25 with an IC50 of 6.8 nM. Vercirnon sodium inhibits CCL25-Induced Chemotaxis of retinoic acid (RA)-Cultured Human T Cells. Vercirnon sodium inhibits RA-cultured cell CCL25-medidated chemotaxis in 100% human AB serum resulted in an IC50 of 141 nM. Vercirnon sodium is a potent inhibitor of CCL25-induced mouse and rat thymocyte chemotaxis with IC50 values of 6.9 nM and 1.3 nM, respectively[1]. |
| In Vivo | Vercirnon (GSK1605786A) sodium (10, 50 mg/kg; s.c.; twice per day; starting at 2 weeks of age until 12 weeks of age) ameliorates the severity of intestinal inflammation in the TNFΔARE mouse model[1]. Animal Model: C57BL/6 mice (TNFΔARE Mouse Model of Terminal Ileitis)[1] Dosage: 10, 50 mg/kg Administration: Subcutaneous; twice per day; starting at 2 weeks of age until 12 weeks of age Result: Resulted in complete protection from the severe inflammation associated with TNF- overexpression at 50 mg/kg. A similar protective effect was also noted with a lower dose. |
| References |
| Molecular Formula | C22H20ClN2NaO4S |
|---|---|
| Molecular Weight | 466.91300 |
| Exact Mass | 466.07300 |
| PSA | 103.40000 |
| LogP | 6.15740 |
| UNII-9NQF0M8R0M |
| Benzenesulfonamide,N-(4-chloro-2-((1-oxido-4-pyridinyl)carbonyl)phenyl)-4-(1,1-dimethylethyl)-,sodium salt |
| Vercirnon sodium [USAN] |
| N-(4-Chloro-2-((1-oxidopyridin-4-yl)carbonyl)phenyl)-4-(1,1-dimethylethyl) benzenesulfonamide,sodium salt |
| Vercirnon sodium |